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Abstract
Background: The impact of haemoglobin concentrations on clinical outcomes is still a controversial issue. To
determine the association between haemoglobin concentrations on admission and clinical outcomes and the
related factors, this study was performed in a Chinese hospital.
Findings: We conducted a retrospective study on 1394 Chinese patients with acute myocardial infarction. Patients
were categorized according to the haemoglobin concentration on admission, and data were evaluated to
determine whether there was an association between the haemoglobin concentrations on admission and 30-day
in-hospital MACEs (major cardiovascular events). Patients with hemoglobin values between 141 and 150 g/L were
used as the reference, the MACEs increased as hemoglobin concentrations fell below 140 g/L or rose > 150 g/L,
with an adjusted OR (odds ratio) of 5.96[95% CI (confidence interval) 2.00 to 17.68, p = 0.0013], 4.39(1.37 to 14.08, p
= 0.0128), 3.99(1.46 to 10.92, p = 0.0071), 3.19(1.27 to 8.05, p = 0.0139), 2.37(0.94 to 6.01, p = 0.0687), 2.11(0.66 to
6.74, p = 0.2065), 2.01(0.60 to 6.68, p = 0.2559) in patients with haemoglobin concentrations <100 g/L, 101-110 g/L,
111-120 g/L, 121-130 g/L, 131-140 g/L, 151-160 g/L, and >160 g/L respectively. Partial correlation analysis showed
that age, albumin and creatinine were significantly associated with hemoglobin concentration.
Conclusions: Our results demonstrated that haemoglobin concentration affected MACEs in patients with acute
myocardial infarction, and that haemoglobin concentration was associated with age, albumin and creatinine.
Background
Myocardial infarction results from the imbalance of the
oxygen supply and demand of the jeopardized myocar-
dium. Anemia has been reported to be present in 15%
of patients presenting with acute myocardial infarction
(AMI) [1] and in 43% of elderly patients with AMI [2].
Anemia has the potential to worsen the myocardial
ischemic insult in AMI, both by decreasing the oxygen
content of the blood supplied to the jeopardized myo-
cardium [3] and by increasing myocardial oxygen
demand through necessitating a higher cardiac output
to maintain adequate systemic oxygen delivery [4].
Therefore, it is hypothesized that haemoglobin (Hb)
concentrations on admission affect the prognosis of
patients with myocardial infarction.
In animal models, higher hemoglobin concentrations
prevent ischemia in the setting of significant coronary
artery stenoses [5,6]. Transfusion of anemic animals up
to 100 g/L Hb with fresh blood reduces infarct size and
improves cardiac function, but, transfusion to 120 g/L
Hb did not demonstrate any additional benefit and was
associated with larger infarcts [7]. In human studies,
anemia has been shown to be an independent risk factor
for adverse cardiovascular outcomes in community
cohorts[8], in patients with heart failure[9,10], in
patients undergoing percutaneous coronary intervention
(PCI) [11] and in acute coronary syndrome[12-16]. In
the cohort study including nearly 40 000 patients with
acute coronary syndrome (ACS), a reverse J-shaped rela-
tionship between baseline hemoglobin values and major
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development of anemia during hospitalization for AMI
was associated with an increased long-term mortality
[18]. But anemia in some studies was not found to have
a higher mortality [15], and blood transfusion in the set-
ting of acute coronary syndromes is associated with
higher mortality [19,20]. Furthermore, the risk factors
relating to hemoglobin concentrations were not investi-
gated in the studies. Therefore, we examined the rela-
tionship between baseline hemoglobin concentration
and cardiovascular clinical outcomes in Chinese patients
with AMI and investigated the risk factors relating to
hemoglobin concentrations.
Methods
Study patients
The study cohort eligible for these analyses consisted
of 1394 patients with AMI hospitalized in Chinese
People’s Liberation Army General Hospital between
Jan 1998 and Aug 2009. Patients with active cancer
(having cancer and hemoglobin concentration < 141 g/
L on admission), significant liver (aspartate amino-
transferase or alanine aminotransferase >40 × 2 U/L
and serum albumin <40 g/L) or renal disease (a creati-
nine > 177 μmol/L), active or recent (past three
months) internal bleeding, known bleeding diathesis
were excluded from these study.
Written informed consents were obtained from the
patients for publication of this short report. This study
protocol has been approved by the committee on
human research of Chinese People’s Liberation Army
General Hospital.
Data collection and group comparisons
B a s e l i n ed a t aw e r ec o l l e c t e dr e t r o s p e c t i v e l yb yu s eo f
a standardized form including past history, smoking
history, family history of coronary heart disease
(CHD), hypertension history, location of myocardial
infarction, left ventricular ejection fraction (LVEF) by
echocardiography in one week after admission, heart
rate (mean value of heart rates within 24 hours after
arrival), blood pressure, laboratory data on admission
(within 24 hours after arrival at the hospital) and
medication.
According to the hemoglobin concentration values on
admission (the first measurement taken within 24 hours
after arrival at the hospital), the patients were divided
into eight categories: Group <100 g/L; Group 101-110
g/L; Group 111-120 g/L; Group 121-130 g/L; Group
131-140 g/L; Group 141-150 g/L; Group 151-160 g/L;
Group >160 g/L for the purpose of evaluating the asso-
ciations among the hemoglobin on admission, various
characteristics of the patient, and major cardiovascular
events (MACEs).
Major cardiovascular events
Major cardiovascular events included cardiac mortality
within 30 days after admission and in-hospital complica-
tions (the development of cardiogenic shock, the occur-
r e n c eo fc o n g e s t i v eh e a r tf a i l ure, postinfarction angina,
and ventricular tachycardia/fibrillation).
Definitions
AMI is defined as typical rise and fall creatine kinase-
MB (CK-MB) of biochemical markers of myocardial
necrosis with at least one of the following: a) ischemic
symptoms; b) development of pathologic Q waves on
the ECG; c) Electrocardiogram (ECG) changes indicative
of ischemia (ST segment elevation or depression); or d)
coronary artery intervention (e.g., coronary angioplasty)
[21].
Cardiogenic shock is defined as hypotension (a systolic
blood pressure of less than 90 mmHg for at least 30
minutes or the need for supportive measures to main-
tain a systolic blood pressure of greater than or equal to
90 mmHg), end-organ hypoperfusion (cool extremities
or a urine output of less than 30 ml/h, and a heart rate
of greater than or equal to 60 beats per minute)[22].
Ventricular tachycardia was defined as three or more
beats of ventricular origin in succession at a rate greater
than 100 beats/minute; ventricular fibrillation defined as
irregular undulations of varying contour and amplitude
on the ECG, with absent distinct QRS and T waves and
hemodynamic compromise requiring direct-current
defibrillation.
Congestive heart failure (CHF) are defined by the
symptoms: exertional dyspnea, orthopnea, shortness of
breath, labored breathing, fatigue at either rest or with
exertion; and signs: rales greater than one-third of the
lung fields, S3 gallop on auscultation, or pulmonary con-
gestion on X-ray film.
Statistical analysis
Baseline characteristics are expressed as mean ± SD or
percentages. The ANOVA (analysis of variance) for con-
tinuous variables was used to compare baseline data
among the groups. Chi-square test was used to compare
percentages among the groups. To evaluate the indepen-
dent relationship betweenh e m o g l o b i na n dM A C E sa t
30 days, multivariable logistic regression (logistic model-
ing with categorical predictors) was used. Hemoglobin
was coded as a multicategory predictor in 10 g/L incre-
ments, and the hemoglobin category that had the lowest
event rate and normal hemoglobin level was used as the
reference group. This approach yielded the following
covariates: age; gender; past history: hypertension, dia-
betes, hyperlipidemia, coronary heart disease, smoking
history; the type of current AMI: STE or NSTE; heart
rate, diastolic pressure, pulse pressure, LVEF, albumin,
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Page 2 of 8creatinine, CK-MB, total cholesterol (TC), triglyceride
(TG), low density lipoprotein cholesterol (LDL-C), high
density lipoprotein cholesterol (HDL-C); index medica-
tions: aspirin, b-blocker, calcium channel blockers
(CCB), nitrates, angiotensin converting enzyme inhibi-
tory (ACEI), angiotensin receptor blocker (ARB), statin,
thrombolysis, anticoagulation and index PCI for AMI
patients. Zero-order correlation analysis (no taking
account of covariates) and partial correlation analysis
(taking account of covariates) were used to analysis the
relation between hemoglobin concentration and related
factors including age, heart rate, blood pressure, pulse
pressure, LVEF, albumin, creatinine, CK-MB, TC, TG,
HDL-C and LDL-C. A value of P < 0.05 was considered
significant. Statistical analysis were performed with SAS
for Windows version 9.1(SAS Institute, Cary, N.C. USA)
and SPSS for Windows version 13(SPSS Inc., Chicago,
IL. USA).
Results
The differences in baseline characteristics among the
groups
Patients baseline characteristics, included age, gender,
heart rate, blood pressure, LVEF and laboratory data,
among eight groups are outlined in Table 1. The differ-
ences in age, gender, diastolic pressure, pulse pressure,
LVEF, albumin, creatinine, TC, TG, and LDL-C among
the eight groups were significant.
The baseline characteristics, included past history,
smoking history, family history of CHD, myocardial
infarction and medication among eight groups are out-
lined in Table 2. The differences in past history of dia-
betes mellitus, hyperlipidemia and CHD, smoking
history, family history of CHD, non-Q wave myocardial
infarction, aspirin, b-blocker, statin, thrombolysis and
PCI among the eight groups were significant.
Among the groups, those with lower baseline hemo-
globin concentrations were more likely to be older, past
history of CAD, non-Q wave myocardial infarction and
diabetes; and less likely to be a smoker and hyperlipide-
mia, and to have family history of CHD; and had lower
LVEF, lower albumin, lower total cholesterol, lower tri-
glyceride, lower diastolic pressure, higher pulse pressure
and higher creatinine.
The association between hemoglobin concentration and
clinical outcomes
Unadjusted clinical outcomes rates
The cardiac death and complications within 30 days
after admission in the eight groups are shown in Table
3. The group with lower hemoglobin concentration on
admission had higher cardiac death, and more likely suf-
fered from cardiogenic shock, congestive heart failure
and postinfarction angina, than the groups with higher
hemoglobin concentration on admission.
The likelihood of cardiogenic shock, heart failure,
postinfarction angina, and cardiac death was signifi-
cantly related to baseline hemoglobin (Table 3, P =
0.0367, <0.0001, 0.005, and <0.0001 for cardiogenic
shock, heart failure, postinfarction angina, and cardiac
death respectively), with the patients at either end of the
hemoglobin spectrum being more likely to have adverse
clinical outcome: cardiac death and cardiogenic shock.
Figure 1 shows the unadjusted OR and 95% CI for 30-
day MACEs in patients with AMI categorized by 10 g/L
hemoglobin increments.
Adjusted clinical outcomes rates
Considering imbalances in important baseline character-
istics, multivariable logistic regression was used to evalu-
ate the independent relationship between hemoglobin
and MACEs after adjustment for a wide range of covari-
ates, including age; gender; past history: hypertension,
diabetes, hyperlipidemia, CAD, smoking history; the
type of current AMI: STE or NSTE; heart rate; diastolic
pressure; pulse pressure; LVEF; albumin; creatinine; CK-
M B ;T C ;T G ;L D L - C ;H D L - C ;i n d e xm e d i c a t i o n s :
aspirin, b-blocker, CCB, nitrates, ACE inhibitor, ARB,
statin, thrombolysis, anticoagulation and PCI. Figure 1
shows the adjusted OR and 95% CI for 30-day MACEs
in patients with AMI categorized by 10 g/L hemoglobin
increments. With the patients with hemoglobin values
of 141 to 150 g/L as the reference, the MACEs
increased as hemoglobin levels fell below 140 g/L, with
an adjusted OR of 5.96(95% CI 2.00 to 17.68, p =
0.0013), 4.39(1.37 to 14.08, p = 0.0128), 3.99(1.46 to
10.92, p = 0.0071), 3.19(1.27 to 8.05, p = 0.0139), 2.37
(0.94 to 6.01, p = 0.0687) in the patients with haemoglo-
bin concentrations <100 g/L, 101-110 g/L, 111-120 g/L,
121-130 g/L, 131-140 g/L, respectively; the MACEs had
a increased tendency as hemoglobin levels were above
150 g/L, with an adjusted OR of 2.11(0.66 to 6.74, p =
0.2065), 2.01(0.60 to 6.68, p = 0.2559) in the patients
with haemoglobin concentrations 151-160 g/L and >160
g/L respectively, as shown in Figure 1.
The factors related to hemoglobin
Zero-order correlation analysis showed that age, dia-
stolic pressure, pulse pressure, TG, albumin, creatinine,
and LVEF were significantly associated with hemoglo-
bin concentration; partial correlation analysis showed
that age, albumin and creatinine were significantly
associated with hemoglobin concentration after con-
trolling related factors, with partial correlation prob-
ability of <0.001, 0.001 and <0.001 respectively, as
shown in Table 4. The controlling factors for the par-
tial correlation included following covariates: age, heart
rate, systolic and diastolic pressure, pulse pressure,
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Page 3 of 8Table 1 Baseline Characteristics in AMI Patients Stratified by Baseline Hemoglobin
Variable <100 g/L
(n = 86)
101-110 g/L
(n = 74)
111-120 g/L
(n = 143)
121-130 g/L
(n = 222)
131-140 g/L
(n = 278)
141-150 g/L
(n = 296)
151-160 g/L
(n = 173)
>160 g/L
(n = 122)
p value
Age (year) 74.0 ± 10.2 71.8 ± 11.7 72.2 ± 11.7 67.5 ± 12.2 63.6 ± 12.0 57.9 ± 12.9 52.7 ± 12.3 53.0 ± 11.8 0.000
Gender(female/male) 36/50 29/45 49/94 61/161 43/235 26/270 7/166 5/117 0.000
Hb(g/L) 86.3 ± 12.1 106.3 ± 2.6 115.9 ± 2.8 125.6 ± 2.8 135.6 ± 2.9 145.4 ± 3.0 155.3 ± 2.9 167.7 ± 6.3 0.000
Heart rate(beats/min) 82.3 ± 20.4 81.4 ± 19.3 79.3 ± 16.3 78.4 ± 17.3 77.5 ± 15.2 75.7 ± 13.4 76.7 ± 13.6 78.5 ± 17.8 0.011
Systolic pressure(mmHg) 127.7 ± 25.7 120.9 ± 22.5 126.2 ± 22.9 123.1 ± 21.2 123.9 ± 20.4 123.2 ± 18.9 125.3 ± 18.1 126.4 ± 21.6 0.281
Diastolic pressure(mmHg) 72.7 ± 15.4 69.2 ± 13.0 71.4 ± 14.8 72.1 ± 12.4 73.5 ± 11.6 73.6 ± 12.7 77.6 ± 11.5 77.8 ± 14.9 0.000
Pulse pressure(mmHg) 55.0 ± 17.3 51.7 ± 18.0 54.8 ± 16.4 51.1 ± 16.1 50.4 ± 17.0 49.6 ± 13.9 47.8 ± 13.1 48.7 ± 14.8 0.000
LVEF(%) 48.9 ± 12.0 47.0 ± 12.0 47.5 ± 11.1 49.0 ± 11.1 51.3 ± 11.3 52.2 ± 9.7 52.6 ± 9.1 53.0 ± 10.4 0.000
Albumin (g/L) 32.6 ± 4.6 33.3 ± 4.6 35.7 ± 4.5 36.9 ± 3.9 37.7 ± 4.1 39.7 ± 4.1 41.2 ± 4.0 41.5 ± 4.3 0.000
Creatinine (μmol/L) 139.9 ± 30.8 101.0 ± 71.9 89.4 ± 56.4 81.1 ± 45.7 77.6 ± 26.7 80.0 ± 51.9 71.9 ± 25.0 81.3 ± 48.0 0.000
CK-MB(u/L) 115.9 ± 194.1 113.8 ± 164.5 132.3 ± 171.3 133.5 ± 200.2 148.9 ± 190.6 143.3 ± 216.0 166.8 ± 211.1 173.1 ± 193.1 0.499
TC(mmol/L) 4.5 ± 1.3 4.4 ± 1.1 4.5 ± 1.3 4.5 ± 1.1 4.6 ± 1.1 4.7 ± 1.1 4.8 ± 1.1 4.8 ± 1.3 0.026
TG(mmol/L) 1.6 ± 1.4 1.5 ± 1.0 1.3 ± 0.6 1.5 ± 1.2 1.7 ± 1.0 1.8 ± 1.0 2.0 ± 1.2 2.1 ± 1.3 0.000
HDL-C(mmol/L) 1.2 ± 0.4 1.2 ± 0.3 1.1 ± 0.3 1.2 ± 0.3 1.2 ± 0.6 1.2 ± 0.3 1.1 ± 0.3 1.2 ± 0.3 0.871
LDL-C(mmol/L) 2.6 ± 1.1 2.2 ± 0.8 2.6 ± 1.1 2.6 ± 0.9 2.7 ± 0.9 2.7 ± 0.9 2.8 ± 0.8 2.8 ± 1.1 0.013
TC: total cholesterol; TG: triglyceride; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol. The data except those in gender item are expressed as mean ± SD.
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8albumin, creatinine, LVEF, CK-MB, TC, TG, HDL-C
and LDL-C.
Discussions
Haemoglobin, as a main oxygen carrier, plays an impor-
tant role in supplying oxygen to tissues. When haemo-
globin decreases, body may increase cardiac output to
maintain the normal metabolic demands of tissues,
which increases work load of heart, and result in myo-
cardial damage [4,5].
The association between haemoglobin concentration and
clinical outcomes
The relationship between hemoglobin concentrations
and cardiovascular outcomes has been reported in a
broad cohort of patients with ACS [15,17,23,24]. But the
association between low hemoglobin concentrations and
adverse cardiovascular outcomes has not been settled.
A lF a l l u j ie ta l[ 1 5 ]e x a m i n e d a database of discharge
abstract information in patients admitted with myocar-
dial infarction included 30,341 patients hospitalized in
1986 and (prethrombolytic era, n = 15,584) and 1996
(thrombolytic era, n = 14,757), anemia in this study
were not found to have a higher mortality. In contrast,
in a large database study of elderly patients with AMI, a
powerful, albeit unadjusted, relationship between hema-
tocrit on admission and all-cause 30-day mortality was
found, there was a dose-response effect, with progres-
sively lower survival rates with more profound degrees
of anemia[12]. Similar results was also reported in the
Table 2 Risk factor, past history, the location of AMI and medication in different group
Variable <100 g/L
(n = 86)
101-110 g/L
(n = 74)
111-120 g/L
(n = 143)
121-130 g/L
(n = 222)
131-140 g/L
(n = 278)
141-150 g/L
(n = 296)
151-160 g/L
(n = 173)
>160 g/L
(n = 122)
p value
Past history
Hypertension(%) 61 (70.9) 46 (62.2) 79 (55.2) 124 (55.9) 143 (51.4) 159 (53.7) 88 (50.9) 65 (53.3) 0.064
Diabetes mellitus(%) 40 (46.5) 19 (25.7) 48 (33.6) 64 (28.8) 58 (20.9) 52 (17.6) 32 (18.5) 18 (14.8) 0.000
Hyperlipidemia(%) 27 (31.8) 29 (39.1) 39 (27.4) 76 (34.2) 111 (39.9) 142 (47.9) 99 (57.0) 74 (60.7) 0.000
CAD(%) 36 (41.9) 28 (37.8) 50 (35.0) 74 (33.3) 69 (24.8) 81 (27.4) 34 (19.7) 30 (24.6) 0.001
Smoking history(%) 16 (18.6) 20 (27.0) 45 (31.5) 71 (32.0) 144 (51.8) 138 (46.6) 97 (56.1) 71 (58.2) 0.000
Family history of CHD(%) 13 (15.1) 16 (21.6) 26 (18.2) 54 (24.3) 78 (28.1) 97 (32.8) 55 (31.8) 38 (31.1) 0.003
Location of AMI
Anterior wall(%) 21 (24.4) 25 (33.8) 45 (31.5) 75 (33.8) 98 (35.3) 123 (41.6) 69 (39.9) 55 (45.1) 0.025
Inferior wall(%) 18 (20.9) 26 (35.1) 46 (32.2) 57 (25.7) 98 (35.3) 100 (33.8) 53 (30.6) 36 (29.5) 0.129
Other wall(%) 9 (10.5) 9 (12.2) 14 (9.8) 26 (11.7) 35 (19.9) 43 (14.5) 21 (12.1) 24 (19.7) 0.356
Non-Q wave MI(%) 38 (44.2) 22 (29.7) 39 (27.3) 71 (32.0) 69 (24.8) 53 (17.9) 31 (17.9) 25 (20.5) 0.000
Indexed medication
Aspirin(%) 59 (68.6) 58 (78.4) 128 (89.5) 203 (91.4) 250 (89.9) 280 (94.6) 164 (94.8) 113 (92.6) 0.000
b-blocker(%) 46 (53.5) 34 (45.9) 69 (48.3) 125 (56.3) 181 (65.1) 187 (63.2) 104 (60.1) 72 (59.0) 0.005
CCB(%) 22 (25.6) 17 (23.0) 46 (47.4) 46 (20.7) 60 (21.6) 71 (24.0) 38 (22.0) 27 (22.1) 0.322
Nitrates(%) 62 (72.1) 52 (70.3) 116 (81.1) 162 (73.0) 207 (74.5) 207 (69.9) 115 (66.5) 86 (70.5) 0.170
ACEI(%) 44 (51.2) 39 (52.7) 74 (51.7) 111 (50.0) 156 (56.1) 179 (60.5) 110 (63.6) 69 (56.6) 0.104
ARB(%) 6 (7.0) 5 (6.8) 8 (5.6) 11 (5.0) 13 (4.7) 19 (6.4) 9 (5.2) 7 (5.7) 0.981
Statin(%) 25 (29.1) 23 (31.1) 57 (39.9) 98 (44.1) 128 (46.0) 160 (54.1) 92 (53.2) 68 (55.7) 0.000
Thrombolysis(%) 4 (4.7) 6 (8.1) 10 (7.0) 27 (12.2) 40 (14.4) 56 (18.9) 27 (15.6) 20 (16.4) 0.002
Anticoagulation(%) 47 (54.7) 42 (56.8) 84 (58.7) 133 (59.9) 179 (64.4) 185 (62.5) 113 (65.3) 87 (71.3) 0.198
PCI(%) 20 (23.3) 33 (44.6) 48 (33.6) 120 (54.1) 178 (64.0) 231 (78.0) 145 (83.8) 93 (76.2) 0.000
CAD: coronary artery disease; CHD: coronary heart disease; CCB: calcium channel blockers; ACEI: ACE inhibitor; ARB: angiotensin receptor blocker; PCI:
percutaneous coronary intervention. The numbers but those in the second line in parentheses are expressed in percentage.
Table 3 MACEs through 30 days
Variable <100 g/L
(n = 86)
101-110 g/L
(n = 74)
111-120 g/L
(n = 143)
121-130 g/L
(n = 222)
131-140 g/L
(n = 278)
141-150 g/L
(n = 296)
151-160 g/L
(n = 173)
>160 g/L
(n = 122)
p value
Cardiogenic shock(%) 9(10.5) 7(9.5) 10(7.0) 16(7.2) 16(5.8) 8(2.7) 5(2.9) 6(4.9) 0.0367
Heart failure(%) 31(36.0) 21(28.4) 24(16.8) 42(18.9) 34(12.2) 24(8.1) 15(8.7) 9(7.4) <0.0001
Postinfarction angina(%) 3(3.5) 8(10.8) 7(4.9) 9(4.1) 7(2.5) 5(1.7) 2(1.2) 5(4.1) 0.0050
VT/VF(%) 5(5.8) 5(6.8) 10(7.0) 12(5.4) 14(5.0) 16(5.4) 12(6.9) 6(4.9) 0.9813
Cardiac death(%) 17(19.8) 13(17.6) 21(14.7) 21(9.5) 21(7.6) 9(3.0) 6(3.5) 10(8.2) <0.0001
MACEs(%) 41(47.7) 29(39.2) 46(32.2) 61(27.5) 56(20.1) 44(14.9) 29(16.8) 24(36.1) <0.0001
The numbers but those in the second line in parentheses are expressed in percentage.
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Page 5 of 8research by Sabatine et al[17], which included 25419
patients with ST-segment elevation myocardial infarc-
tion (STEMI) and 14 503 patients with NSTE from 16
Thrombolysis In Myocardial Infarction trials, and a
reverse J-shaped relationship between hemoglobin con-
centrations and clinical outcomes was found: in patients
with STEMI, the cardiovascular mortality increased as
hemoglobin concentrations fell below 14 g/dL and
hemoglobin values rose above 17 g/dL, compared with
hemoglobin concentrations between 14 and 15 g/dL; in
patients with NSTE ACS, the cardiovascular death, myo-
cardial infarction, or recurrent ischemia increased as the
hemoglobin fell below 11 g/dL and hemoglobin values
rose above 16 g/dL, compared with those with hemoglo-
bin 15 to 16 g/dL.
But in Chinese AMI, the relationship between hemo-
globin concentrations and cardiovascular outcomes has
not been reported up till now. In this research of Chi-
nese AMI, from single medical center, a reverse J-
shaped (Figure 1) relationship between hemoglobin
concentrations and clinical outcomes was also found,
with patients at either end of the hemoglobin spectrum
being more likely to have adverse clinical outcomes, sig-
nificantly for those with haemoglobin concentrations
<140 g/L, insignificantly but tendentiously for with hae-
moglobin concentrations >150 g/L. Compared with
patients with haemoglobin concentrations 141-150 g/L,
those with haemoglobin concentrations <140 g/L had
more cardiac death, cardiogenic shock and heart failure,
and those with haemoglobin concentrations >150 g/L
also had more cardiac death, cardiogenic shock and
postinfarction angina. Through Sabatine and his collea-
gues[17] have reported a similar results, this report
adjusted some important risk factors for MACEs, such
as CK-MB and LVEF, which were not adjusted in Saba-
tine and his colleagues’ research. Otherwise, our
research had different clinical outcomes, which included
cardiogenic shock and heart failure.
The worse outcomes observed in patients with AMI
with either end of the hemoglobin spectrum might be
Figure 1 ORs and 95% CIs for association between baseline hemoglobin concentration and the MACEs through 30 days in patients
with AMI . Adjusted for gender; age; past history: hypertension, diabetes, hyperlipidemia, CAD, smoking history; the type of current AMI: STE or
NSTE; heart rate; diastolic pressure; pulse pressure; LVEF; albumin; creatinine; CK-MB; TC; TG; LDL-C; HDL-C; index medications: aspirin, b-blocker,
CCB, nitrates, ACE inhibitor, ARB, statin, thrombolysis, anticoagulation and PCI.
Table 4 Zero order and partial correlation analysis of factors related to hemoglobin
Variable Mean ± SD Zero-order correlation
coefficient
Zero-order correlation
probability
Partial correlation
coefficient
Partial correlation
probability
Age 62.2 ± 13 years -0.530 0.000 -0.368 0.000
Diastolic pressure 71.3 ± 13.2 mmHg 0.174 0.007 0.000 1.000
Pulse pressure 53.8 ± 14.8 mmHg -0.177 0.007 0.000 1.000
Albumin 37.7 ± 4.3 g/L 0.447 0.000 0.226 0.001
Creatinine 87.4 ± 59.2 mmol/L -0.339 0.000 -0.288 0.000
TG 1.5 ± 0.9 mmol/L 0.210 0.001 0.017 0.798
LVEF 50.7 ± 11.1% 0.148 0.023 0.082 0.226
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Page 6 of 8explained by theory that anemia could decrease oxygen
delivery to tissues, therefore attenuate the ability of
collateral flow from nearby patent vessels to limit the
extent of myocardial necrosis and peri-infarct ischemia,
meanwhile anemia increase myocardial oxygen demand
through necessitating a higher work load; and that
higher haemoglobin concentration would increase
blood viscosity, which decrease oxygen delivery to tis-
sues [25].
The factors related to haemoglobin concentration
Anemia is common in elder people, about 12.5% of
patients aged 71 years or older had anemia [26]. Anemia
accounted for 24% of geriatric hospitalized population in
some reports [2]. A positive relationship between hae-
moglobin concentration and serum albumin concentra-
tion was reported in the elderly [27]. A direct
relationship between haemoglobin concentration and
serum albumin level was found in hemodialysis patients
[28,29]. Age was also found to be significantly associated
with hemoglobin concentrations (P < 0.001) [29]. But
the association between age and haemoglobin concen-
tration has not been reported in AMI patients.
In this paper, the factors related to haemoglobin con-
centrations were analysed. Age, diastolic pressure, TG,
albumin and LVEF were found to be significantly asso-
ciated with hemoglobin concentration (zero-order corre-
lation probability < 0.01); After careful controlling these
relevant factors, age, creatinine, and albumin were sig-
nificantly associated with hemoglobin concentration
(partial correlation probability < 0.01). The older, those
with higher creatinine level and those with lower albu-
min level were more likely to have lower hemoglobin
concentrations. Hemoglobin concentration falls with age
and creatinine increase, and rises with albumin increase.
There are several possible explanations for these find-
ings. First, elderly people might easily suffer from ane-
mia because hematogenous function declines with aging
[30-32]. Second, albumin is a marker of nutrition. Low
albumin level means protein-calorie malnutrition to
some extent [33,34]. Shortened red blood cells survival,
decreased erythropoietin secretion by kidney, and con-
current deficiencies of iron, pyridoxine and folate have
been reported to contribute to anemia [34].
Although the association between hemoglobin concen-
trations and adverse cardiovascular events was demon-
strated in this and other researches [17,18,35], the
beneficial effect of transfusion on clinical outcomes
remain to be settled.
The studies of transfusion effect on clinical outcomes
of anemia have yielded conflicting results. In elderly
patients with AMI, transfusion appeared to be beneficial
if the hematocrit was < 33% [12]. In contrast, Transfu-
sion was reported to have adverse impact on the
prognosis of acute coronary syndromes in some nonran-
domized trails. Transfusion in anemic patients admitted
w i t ha c u t ec o r o n a r ys y n d r o m el e dt oas i g n i f i c a n t
increase in 30-day recurrent MI or death [19,20], espe-
cially for NSTE ACS [17]. Therefore, transfusion effect
on clinical outcomes of anemia remains to be further
investigated.
The limitation of this study
As this is a retrospective study, some potential limita-
tions of this study should be considered. The present
study was from single large Chinese medical center,
which might limit generalizability of our findings. Man-
agement strategy was not included in variables. There
may be some differences among groups in management
strategy, as was reported in some studies [17]. Differ-
ences in treatment among the groups might have the
potential to confound our analyses. The cause of anemia
in patients in the present study was not known, the dif-
ferent causes might have residual confounding. Because
the active bleeding was not included in this study, the
anemia exactly means chronic anemia. Although we
cannot rule out the possibility that we were unable to
adjust for this known and other unknown confounders,
given the breadth of covariates adjusted for in the pre-
sent analyses, the impact is likely to be small.
Since this data was from single large center, which
avoid the bias from different centers, unity of data was
guaranteed.
Conclusions
Anemia and too high hemoglobin concentrations might
lead to adverse clinical outcome, and age, albumin and
creatinine are significantly associated with anemia. So
we should pay much attention to the AMI with anemia
and the elderly to improve the prognosis.
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